Back to Research Home
NBIXNeurocrine Biosciences Inc
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · Large
$142.70−0.41%
As of 23 Oct 2026Mkt cap $16.0B
Stage 13
WATCH
Fundamentals
57.3/75
Technical
10.3/15
Independent
67.6/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- +2.7%
- 3M
- −19.1%
- 6M
- +11.8%
- 1Y
- +0.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 20.9xHist median 35.7x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 14.3%
- Operating margin
- 21.6%
- FCF margin
- 26.2%
- Current ratio
- 3.4x
Growth
- Revenue growth
- +21.4%Latest FY YoY
- Revenue CAGR
- +26.0%
- EPS CAGR
- +50.1%
- FCF CAGR
- +33.9%
Capital
- Share-count trend
- +0.7%3Y annualised
- Net cash
- $242M-0.3x OCF
Annual trend
- CAGR 2021–2025
- +26.0%
- Latest · 2025
- $3B
- YoY
- +21.4%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-02
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded